Cause‐specific death in adults with type 1 diabetes and type 2 diabetes: Insights from the UK Biobank

Muthiah Vaduganathan has received research grant support, served on advisory boards, or had speaker engagements with American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, BMS, Boehringer Ingelheim, Chiesi, Cytokinetics, Lexicon Pharmaceuticals, Merck, Novartis, Novo Nordisk, Pharmacosmos, Relypsa, Roche Diagnostics, Sanofi, and Tricog Health, and participates on clinical trial committees for studies sponsored by AstraZeneca, Galmed, Novartis, Bayer AG, Occlutech, and Impulse Dynamics. Michael C. Honigberg reports advisory board service for Miga Health; receiving personal fees from Comanche Biopharma; serving as site principal investigator for Novartis; and receiving grants from the National Heart, Lung, and Blood Institute, the American Heart Association, Patient-Centered Outcomes Research Institute, and Genentech outside the submitted work. John W. Ostrominski and So Mi Jemma Cho have no disclosures to report. The peer review history for this article is available at https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/dom.16009. UK Biobank data are available by application (https://www.ukbiobank.ac.uk/register-apply/).